Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
NCT07160647Phase 2Active, not recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in colorectal cancer (CRC), sponsored by Sir Run-Run Shaw Hospital. Started Aug 2025; status: active, not recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07160647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07160647.